New serum combo takes on stubborn toenail fungus
NCT ID NCT06175013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested two topical serums for treating toenail fungus (onychomycosis). 44 adults with mild to moderate infection applied one or both serums daily for 112 days. Researchers measured the change in healthy nail area using photos. The goal was to see if using both serums together works better than one alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Sérum PURIFIANT and Sérum BOOSTER (topical serums for nail fungus)
- What this could lead to
- If it works, this could offer a non-drug option for treating toenail fungus, potentially improving nail appearance without pills or surgery.
- What could go wrong
- This is a small, early-stage study with only 44 people. The results may not apply to everyone, and the products might not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
44 people
The number who actually took part.
- Started
-
Nov 2024
- Finished
-
Jun 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient having given freely her/his informed, written consent. * Patient having a good general health. * Age: more than 18 years. * Patient cooperative and aware of the devices' modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected. * Patient being psychologically able to understand information and to give his/her consent. * Patient with nails superficial onychomycosis on at least one great toenail or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement \<2/3 of the tablet) * Patient with slight to moderate impact of thickness of the nail and no deformation of the nail. * Patient with slight to moderate impact of thickness of the nail and no deformation of the nail. * Patient with positive KOH staining. * Women of childbearing potential should use an accepted contraceptive regimen (to investigator's discretion) since at least 12 weeks before the beginning of the study, during all the study. Exclusion Criteria: * Pregnant or nursing woman or planning a pregnancy during the investigation. * Patient considered by the investigator likely to be non-compliant with the protocol. * Patient enrolled in another clinical trial during the test period. * Patient having a known allergy or hypersensitivity to one of the constituents of the tested products. * Patient with unstructured nail, severe microcracking or severe onycholysis. * Patient with nails and nails contour with severe lesions * Patient having used any systemic antifungal treatment in the last 6 months before inclusion. * Patient having used any topical antifungal treatment in the last 3 months before inclusion. * Patient with a condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk. * Patient suffering from serious or progressive diseases (to investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, HIV, lichen planus, immunosuppressive pathology, chronic venous insufficiency, Peripheral Arterial Obstructive Disease, delay or lack of ungual growth … * Patient with cutaneous pathology on studied zone (onychogryphosis, congenital ungual deformation, toe deformation or of the foot, Hallux Valgus, Hallux rigidus, Hallux extensus, toe claws or other pathologies than onychomycosis like angioma, dermatitis…).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Onychomycosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Insight Research
Quatres Bornes, Mauritius
More trials for these conditions
Other studies related to the condition(s) this trial covers.